[{"id":"b830c833-61a0-434d-8a29-24074697ffb9","acronym":"DURAFAK","url":"https://clinicaltrials.gov/study/NCT05512208","created_at":"2022-08-23T14:55:32.872Z","updated_at":"2025-02-25T15:27:34.112Z","phase":"Phase 2","brief_title":"A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib","source_id_and_acronym":"NCT05512208 - DURAFAK","lead_sponsor":"University of Oklahoma","biomarkers":" BRAF • NF1 • RAS","pipe":" | ","alterations":" BRAF mutation • RAS mutation","tags":["BRAF • NF1 • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 02/06/2023","start_date":" 02/06/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2025-02-10"},{"id":"f14e50a7-0299-4bd6-adff-9bd98c8ffea6","acronym":"DDU RAF/MEK","url":"https://clinicaltrials.gov/study/NCT02407509","created_at":"2021-01-17T17:47:34.394Z","updated_at":"2024-07-02T16:35:13.413Z","phase":"Phase 1","brief_title":"Phase I Trial of VS-6766 Alone and in Combination With Everolimus","source_id_and_acronym":"NCT02407509 - DDU RAF/MEK","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Avmapki (avutometinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 06/17/2013","start_date":" 06/17/2013","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2024-03-21"},{"id":"61330035-2bc7-439b-bba8-448926a17e6f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00096434","created_at":"2021-01-18T00:18:05.214Z","updated_at":"2024-07-02T16:35:15.818Z","phase":"Phase 2","brief_title":"Sorafenib in Treating Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT00096434","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 09/01/2004","start_date":" 09/01/2004","primary_txt":" Primary completion: 06/01/2006","primary_completion_date":" 06/01/2006","study_txt":"","study_completion_date":"","last_update_posted":"2024-03-07"},{"id":"a908832d-a81e-40f3-9e03-9eb6223d1ad7","acronym":"RAMP-202","url":"https://clinicaltrials.gov/study/NCT04620330","created_at":"2021-01-19T20:34:21.364Z","updated_at":"2024-07-02T16:35:23.520Z","phase":"Phase 2","brief_title":"A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04620330 - RAMP-202","lead_sponsor":"Verastem, Inc.","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • KRAS G12V • KRAS G12","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • KRAS G12V • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Completed","enrollment":" Enrollment 90","initiation":"Initiation: 12/31/2020","start_date":" 12/31/2020","primary_txt":" Primary completion: 08/29/2023","primary_completion_date":" 08/29/2023","study_txt":" Completion: 12/12/2023","study_completion_date":" 12/12/2023","last_update_posted":"2024-01-12"},{"id":"2188e1a4-494f-4dad-8033-4ac6b374cbbc","acronym":"FRAME","url":"https://clinicaltrials.gov/study/NCT03875820","created_at":"2021-01-17T17:43:26.582Z","updated_at":"2024-07-02T16:35:43.556Z","phase":"Phase 1","brief_title":"Phase I Trial of Defactinib and VS-6766.","source_id_and_acronym":"NCT03875820 - FRAME","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" KRAS • RAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12V • RAS mutation • KRAS G12","tags":["KRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12V • RAS mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 87","initiation":"Initiation: 12/12/2017","start_date":" 12/12/2017","primary_txt":" Primary completion: 04/30/2023","primary_completion_date":" 04/30/2023","study_txt":" Completion: 10/31/2023","study_completion_date":" 10/31/2023","last_update_posted":"2023-07-10"},{"id":"fa153fa1-88be-494d-a000-63ab41769eb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00454194","created_at":"2021-01-18T01:36:36.230Z","updated_at":"2024-07-02T16:37:24.233Z","phase":"Phase 2","brief_title":"Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT00454194","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" FLT1","pipe":"","alterations":" ","tags":["FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 110","initiation":"Initiation: 09/01/2007","start_date":" 09/01/2007","primary_txt":" Primary completion: 07/01/2010","primary_completion_date":" 07/01/2010","study_txt":" Completion: 05/01/2013","study_completion_date":" 05/01/2013","last_update_posted":"2017-03-21"}]